首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1900030

疼痛管理治疗市场规模、份额和成长分析（按药物类别、适应症、通路和地区划分）－2026-2033年产业预测

Pain Management Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (NSAIDs, Anesthetics), By Indication (Arthritic Pain, Neuropathic Pain), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 276 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球疼痛管理药物市场规模预计在 2024 年达到 815.3 亿美元，从 2025 年的 844.7 亿美元增长到 2033 年的 1120.9 亿美元，在预测期（2026-2033 年）内复合年增长率为 3.6%。

疼痛管理治疗市场正日益采用多管齐下的方法来有效治疗急性和慢性疼痛。虽然医生通常会将疼痛管理纳入医疗程序，但复杂的病例往往需要专门的疼痛管理干预措施。这个专业领域涵盖多种疾病，包括纤维肌痛、神经病变疼痛、慢性下背痛、关节炎、术后疼痛、癌症疼痛和偏头痛。然而，由于政府和製药公司削减资金，导致疼痛倡导组织的影响力和资金筹措减少，市场成长面临挑战。这些组织在提高公众意识和推广治疗方案方面发挥着至关重要的作用，因此其影响力的下降可能会阻碍疼痛管理治疗的整体进展，并影响这一重要医疗保健领域未来的发展机会。

全球疼痛管理治疗市场驱动因素

全球疼痛管理治疗市场的扩张受到多种疾病日益普遍的显着影响，这些疾病会导致各种形式的疼痛和不适。溃疡、骨关节炎、慢性关节炎、多发性硬化症、癌症和糖尿病神经病变等疾病都是常见的疼痛原因，需要有效的治疗方案。疼痛管理疗法能够有效应对从急性发作到慢性疼痛等各种类型的疼痛，从而推动了市场需求。此外，人们越来越倾向于采取积极主动的疼痛管理策略，这进一步促进了这一重要医疗保健领域的成长，凸显了这些疗法在改善患者生活品质方面发挥的关键作用。

限制全球疼痛管理治疗市场发展的因素

阻碍全球疼痛管理治疗市场成长的关键因素之一是人们对处方药物滥用问题的日益关注。这些药物通常并非依照医护人员的指导服用，其滥用会带来严重的健康风险，而这些风险往往被低估。此类滥用可能导致严重的健康併发症，在极端情况下甚至可能致命。大众对这些危险的认识不断提高，可能会促使对处方笺止痛药进行更严格的审查和监管，从而影响市场动态，并促使患者寻求其他疼痛管理方案。

全球疼痛管理药物市场趋势

全球疼痛管理治疗市场正经历显着的转变，个人化医疗、生物製药和快速起效的生活方式疗法正成为主流，目前这些疗法在研发领域占据主导地位，占新治疗方法总数的70%以上。这一转变反映出人们对疼痛管理复杂性的认识不断加深，医疗服务提供者正在寻求能够提高疗效并最大限度减少副作用的个人化治疗方案。此外，生物技术和基因组学的进步也促进了标靶治疗的开发，使其更贴近患者的个别需求。随着对创新有效止痛方案的需求不断增长，预计市场将在治疗方法模式上进一步发展，更加贴近以患者为中心的护理模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

CSL Behring（Australia）
Takeda Pharmaceutical Company Limited（Japan）
Pharming Group NV（Netherlands）
BioCryst Pharmaceuticals, Inc.（USA）
Ionis Pharmaceuticals, Inc.（USA）
Sanofi SA（France）
Adverum Biotechnologies, Inc.（USA）
KalVista Pharmaceuticals, Inc.（USA）
Attune Pharmaceuticals, Inc.（USA）
Arrowhead Pharmaceuticals, Inc.（USA）
Amgen Inc.（USA）
BioMarin Pharmaceutical Inc.（USA）
Catalyst Biosciences, Inc.（USA）
RUCONEST（Pharming Group NV, Netherlands）
Haegarda（CSL Limited, Australia）
Firazyr（Shire plc, UK）
Shire plc（UK）
Dyax Corp.（USA）
Adverum Biotechnologies, Inc.（USA）
Amgen Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35F2004

Global Pain Management Therapeutics Market size was valued at USD 81.53 Billion in 2024 and is poised to grow from USD 84.47 Billion in 2025 to USD 112.09 Billion by 2033, growing at a CAGR of 3.6% during the forecast period (2026-2033).

The pain management therapeutics market reveals a growing trend toward employing a multidisciplinary approach to treat both acute and chronic pain effectively. Physicians routinely integrate pain control into medical procedures but often require specialized pain management interventions for complex cases. This specialty addresses various conditions, including fibromyalgia, neuropathic pain, chronic back pain, arthritis, post-operative pain, cancer pain, and migraines. However, the market growth faces challenges due to the declining influence and funding of pain advocacy organizations, stemming from cuts from both government and pharmaceutical sponsors. As these organizations play a crucial role in promoting awareness and advancing treatment options, their diminished power may hinder the overall progress in pain management therapies, affecting future opportunities in this essential healthcare segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pain Management Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pain Management Therapeutics Market Segments Analysis

Global Pain Management Therapeutics Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics and Others. Based on Indication, the market is segmented into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis and Others. Based on Distribution channel, the market is segmented into Online Pharmacy, Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pain Management Therapeutics Market

The expansion of the global pain management therapeutics market is significantly influenced by the rising prevalence of multiple diseases, which bring about various forms of pain and discomfort. Conditions such as ulcers, osteoarthritis, chronic arthritis, multiple sclerosis, cancer, and diabetic neuropathy are common sources of pain that necessitate effective management solutions. The effectiveness of pain management therapies in addressing a wide range of pain types, from acute episodes to chronic conditions, is driving demand. Additionally, an increasing preference for proactive pain management strategies is further propelling the growth of this vital healthcare sector, highlighting the essential role these therapeutics play in improving quality of life.

Restraints in the Global Pain Management Therapeutics Market

One significant factor that may hinder the growth of the Global Pain Management Therapeutics market is the rising concern surrounding prescription drug abuse. The misuse of these medications, often taken in ways not directed by healthcare professionals, poses considerable health risks that are frequently underestimated. Such abuse can lead to severe health complications and, in extreme cases, even result in fatal outcomes. As public awareness of these dangers increases, it may foster greater scrutiny and regulation surrounding prescription pain medications, which in turn could impact the market dynamics and drive patients towards alternative pain management solutions.

Market Trends of the Global Pain Management Therapeutics Market

The Global Pain Management Therapeutics market is experiencing a significant trend towards personalized medicine, biologics, and rapid-acting lifestyle therapies, which now dominate the developmental landscape, constituting over 70% of new treatments. This shift reflects a growing recognition of the complexity of pain management, as healthcare providers seek tailored approaches that enhance efficacy and minimize side effects. Moreover, advancements in biotechnology and genomics are facilitating the creation of targeted therapies that align more closely with patient-specific needs. As the demand for innovative and effective pain relief solutions rises, the market is likely to see further evolution in its therapeutic offerings, aligning closely with patient-centric care models.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technology Analysis
Patent Analysis

Global Pain Management Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
NSAIDs
Anesthetics
Anticonvulsants
Anti-migraine Agents
Antidepressants
Opioids
Nonnarcotic Analgesics
Others

Global Pain Management Therapeutics Market Size by Indication & CAGR (2026-2033)

Market Overview
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia
Muscle Sprain/Strain
Bone Fracture
Acute Appendicitis
Others

Global Pain Management Therapeutics Market Size by Distribution channel & CAGR (2026-2033)

Market Overview
Online Pharmacy
Hospital Pharmacy
Retail Pharmacy

Global Pain Management Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Class, Indication, Distribution channel)
- US
- Canada
Europe (Drug Class, Indication, Distribution channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Indication, Distribution channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Indication, Distribution channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Indication, Distribution channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharming Group N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioCryst Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KalVista Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Attune Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arrowhead Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalyst Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RUCONEST (Pharming Group N.V., Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haegarda (CSL Limited, Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Firazyr (Shire plc, UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dyax Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments